Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation

Frontiers in Immunology

Xuefang Cao¹  Sarah Sunshine²  Long Wu³  Forat Lutfi⁴ 

[1] Department of Microbiology and Immunology, School of Medicine, University of Maryland Baltimore, Baltimore, MD, United States;Department of Ophthalmology and Visual Sciences, Marlene and Stewart Greenebaum Comprehensive Cancer, University of Maryland Medical Center, Baltimore, MD, United States;Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Baltimore, Baltimore, MD, United States;Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD, United States;

关键词: CD27;    CD70;    immunotherapy;    allogeneic hematopoietic cell transplant (alloHCT);    graft-versus-host disease (GVHD);   

DOI  :  10.3389/fimmu.2021.715909

来源: DOAJ

【 摘 要 】

Immune checkpoint inhibitor therapies and allogeneic hematopoietic cell transplant (alloHCT) represent two distinct modalities that offer a chance for long-term cure in a diverse array of malignancies and have experienced many breakthroughs in recent years. Herein, we review the CD27-CD70 co-stimulatory pathway and its therapeutic potential in 1) combination with checkpoint inhibitor and other immune therapies and 2) its potential ability to serve as a novel approach in graft-versus-host disease (GVHD) prevention. We further review recent advances in the understanding of GVHD as a complex immune phenomenon between donor and host immune systems, particularly in the early stages with mixed chimerism, and potential novel therapeutic approaches to prevent the development of GVHD.

【 授权许可】

Unknown